Inhibition of cyclooxygenase-independent platelet aggregation by sodium salicylate.
The effect of acetylsalicylic acid (ASA) on platelet aggregation (PA) and thromboxane A2 (TxA2) formation was investigated in vitro and ex vivo after 1 g or 300 mg ASA administration to healthy subjects. 50-100 microM ASA inhibited PA by single aggregating agent such as platelet aggregating factor (PAF) or epinephrine and reduced to less than or equal to 5% of control platelet TxB2 formation, but did not influence PA by epinephrine plus PAF. The latter was inhibited by increasing ASA concentration. In samples incubated with 100 microM ASA and stimulated with epinephrine plus PAF, PA could be inhibited by the addition of 100-300 microM sodium salicylate. After 300 mg-1 g ASA administration to healthy subjects, the inhibition of PA by epinephrine plus PAF was more marked by highest doses of ASA. This study suggests that aspirin inhibits PA with a cyclooxygenase-independent mechanism; this effect is mediated, at least in vitro, by salicylic acid.
Violi
F
F
Institute of Clinical Medicine I, University of Rome La Sapienza, Policlinico Umberto I, Italy.
Alessandri
C
C
Praticò
D
D
Guzzo
A
A
Ghiselli
A
A
Balsano
F
F
D000328:Adult; D001241:Aspirin / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D010972:Platelet Activating Factor / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology*; D012980:Sodium Salicylate / Q000097:blood / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000096:biosynthesis
D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D013928:Thromboxane A2; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin; D012980:Sodium Salicylate; D004837:Epinephrine